Introduction {#S1}
============

Chronic obstructive pulmonary disease (COPD) is a chronic progressive disease ([@B66]). Its pathological features mainly include irreversible airway obstruction, mucus secretion, and inflammation ([@B9]). Fifty years ago, it had prompted the establishment of the Department of Pulmonary Diseases. Unfortunately, with the world's population aging rapidly, COPD has become an increasingly serious problem ([@B19]). The Global Burden of Disease Study (GBDS) had estimated ∼299 million patients to have COPD, worldwide, in 2017 ([@B29]). In 2016, ∼2.93 million patients across the world died of the disease due to its high incidence rate. By 2040, the number of deaths due to COPD is expected to be double of that in 2016, which implies ∼4.41 million deaths due to COPD ([@B25]). The above data, however, does not include the patients with COPD who died of cardiovascular disease ([@B8]), and those with some cardiovascular diseases along with airflow restriction ([@B27]). Therefore, the global mortality caused by COPD is remarkably underestimated, and in near future, it could pose a serious public health concern. For many years, the clinical treatment of COPD has focused on relieving patients' symptoms, and improving their health and quality of life. However, till date, it has remained very difficult to alter the progress of this disease through treatment. COPD is a heterogeneous disease, which may need precise and personalized therapeutic approach ([@B34]). Moreover, early diagnosis of the disease would be necessary, before the occurrence of disability or irreversible lung structural changes ([@B46]). The best way to solve this problem would be to explore the biomarkers of COPD and identify new therapeutic targets.

COPD is a complex disease affected by environmental factors (smoking or drugs); therefore, its pathological mechanism is driven by genetic and epigenetic variation ([@B64]; [@B84]). Through genome-wide genetic association studies (GWAS), many COPD-susceptible gene loci, such as *FAM13A* ([@B16]; [@B13]), *CHRNA* 3/5 ([@B61]; [@B33]) and *HHIP* ([@B61]), had been identified previously ([@B88], [@B90], [@B89]; [@B31]; [@B43]; [@B69]; [@B83]; [@B11]). Interestingly, many single nucleotide polymorphisms related to COPD were found in the non-coding region and intron regulatory regions of the gene; this result was consistent with many complex diseases ([@B35]; [@B51]). These single nucleotide polymorphisms may be speculated to be involved in the regulation of epigenetic modification. Some differential methylated sites (CPGs), unrelated to GWAS but closely related to those regarding smoking (the main exposure factor of COPD), have potential significance in COPD susceptibility ([@B64], [@B65]; [@B84]). Therefore, genetic variation and environmental exposure mediated by epigenetic modification may enhance the risk of COPD ([@B64]).

Epigenetic modification mainly includes DNA methylation and various post-translational modifications of histones (histone PTM, including histone acetylation, methylation, phosphorylation, ubiquitination and sulfonation). Among them, COPD is mainly related to histone acetylation. Histone deacetylase is the key enzyme to control the proinflammatory cytokines related to COPD ([@B6]). The balance of histone acetylation/deacetylation in COPD patients will shifted toward acetylation ([@B78]). The imbalance of histone acetylation and deacetylation changes the nucleosome structure in the transcription of inflammatory cytokines, affects the expression of inflammatory genes ([@B57], [@B56]). This leads to the change of gene expression profile in COPD patients ([@B78]).

DNA methylation (DNAm) is a tissue-specific epigenetic modification involved in the regulation of gene expression ([@B84]). It plays an important role in many chronic complex diseases, like cancer ([@B47]) and aging ([@B38]), and is the basis of normal physiological development. Many studies, till date, have confirmed DNA methylation, related to COPD, to be a potential biomarker for disease prevention, diagnosis, and prognostic evaluation ([@B64]; [@B76]). Furthermore, its reversibility makes it an attractive candidate for designing disease biomarkers and drugs. In this review, we focused on the role of DNAm as biomarkers and disease mediators in different tissue samples from patients with COPD.

Biomarker in Blood {#S2}
==================

Blood samples from patients with COPD had previously been reported to show hypomethylation of DNA, which is related to severity of the disease ([@B93]). Some studies had suggested DNA hypomethylation to be related to oxidative stress (OS) via various mechanisms ([@B24]; [@B36]; [@B26]). The redox state of cells, with higher degree of oxidation, may lead to the reduction of DNAm through redox regulation of related enzymes, such as SAM-dependent methyltransferase ([@B24]). In an environment with higher level of oxidation, the activity of methionine adenosyltransferase is decreased, which in turn catalyzes the addition of methionine to adenosine to synthesize SAM ([@B59]). The important role of OS in COPD has now been confirmed ([Figure 1](#F1){ref-type="fig"}; [@B91], [@B92], [@B94]); the characteristics of hypoxia in COPD can enhance OS by increasing ROS production at the level of mitochondrial respiratory chain ([@B10]; [@B37]). In contrast, Angelo Zinellu et al. had reported DNA hypomethylation in the blood of patients with COPD to be related to disease severity, although there was no significant correlation between DNAm and OS index ([@B93]). This may be due to the relatively small sample size of the study or the lack of severely unstable patients with COPD (particularly with high oxidative stress). At the same time, [@B64] had screened 27578 CpG loci in subjects with COPD, by using the HumanMethylation27 array (Illumina, San Diego, CA, United States). A total of 349 CpG loci was found to be significantly related to the susceptibility and severity of COPD. Gene ontology analysis, based on these CpGs, suggested the involvement of immune and inflammatory system pathways, stress response, and external stimulation. Hypomethylation of *SERPINA1* and fucosyltransferase-7 (*FUT7*) genes was found to be closely related to COPD and pulmonary dysfunction. Recently, the haplotypes of two major alleles of *SERPINA1* were found to be related to reduced risk of COPD ([@B62]). *SERPINA1* gene encodes a sialic acid protein called α-1 antitrypsin (AAT), whose main function is to protect the lower respiratory tract from degradation by neutrophil elastase ([@B71]). AAT deficiency is generally believed to be the most important genetic risk factor of COPD. Decrease of α-1 antitrypsin level in circulation leads to the increase of elastase activity in pulmonary neutrophils; it is the imbalance of protease--antiprotease that leads to lung remodeling ([@B7]). *FUT7* encodes sialyl Lewis X (SLeX), which can promote leukocyte migration to inflammatory tissue ([@B53]). Furthermore, the SLeX is a ligand of E-selectin (ES), which is increased in patients with COPD ([@B20]). Therefore, future research should focus on whether the relative hypomethylation of *FUT7* could change the peripheral expression of SLex and eventually lead to the transfer of neutrophils to the lung. If this hypothesis could be confirmed, it will be another exciting and biologically credible way. Some new differential methylation sites related to COPD had been identified in the DNA of Korean blood samples, including cg03559389 (*DIP2C*) and a rare variant (rs140198372) of cg19904425 (*SERPINA 12*) ([@B44]). Among them, the *DIP2C* mutation was found in lung cancer samples ([@B28]) and *SERPINA12* was reported to be related to airflow restriction ([@B39]). For the systematic evaluation of COPD as well as DNAm of peripheral blood in a population-based study, no consistent CpG locus was found in the study of COPD status or that of lung function value ([@B48]). Large-scale research on vertical design to solve reverse causality may prove to be a more fruitful research approach.

![Mechanism for the development of COPD driven by oxidative stress. Exogenous oxidants from the environment and endogenous oxidants (released by activated neutrophils, alveolar macrophages and epithelial cells) lead to the production of reactive oxygen species and cause lung tissue damage. It mainly includes lipid peroxidation, Protein damage, DNA damage and Altering signal pathway. **(A)** Lipid peroxidation results in the hydrolysis of phospholipids in the cell membrane and changes in the structure and permeability of the cell membrane. Arachidonic acid produced by hydrolysis of phosphoric acid molecules, its metabolites thromboxane, prostaglandin E and leukotriene C4 are involved in the inflammatory process. **(B)** The inactivation of α1-AT breaks the balance between protease and anti-protease, which do great damage to elastin and eventually leads to emphysema. **(C)** Gene expression of inflammatory mediators induced by DNA damage. **(D)** Oxidative stress changes TNF-α-mediated signaling pathway, which leads to increased mucus secretion and ciliated cell dysfunction. ROS, reactive oxygen species; AA, arachidonic acid; α1-AT, alpha-1-antitrypsin; Nrf2, nuclear factor erythroid-2-related factor2; HSF, heat shock transcription factor; NF- kB, Nuclear Factor-κB.](fcell-08-00585-g001){#F1}

Blood biomarkers are useful for the assessment of systemic properties of COPD ([@B23]). Compared to lung tissue samples, the risk in blood sampling is lower. In addition, sampling of blood samples can be easily repeated, which is beneficial for longitudinal monitoring of disease progression. Compared to other minimally invasive biological samples (such as urine or sputum), blood samples have a wider range of application, more repeatability, and are less time-consuming. These characteristics make blood sampling more practical in large-scale research ([@B68]).

Biomarker in Sputum {#S3}
===================

Methylation of *P16* and *GATA4* promoter in sputum samples was assumed to be an early biomarker of COPD ([@B73]; [@B52]). *GATA4* is a transcription regulator for many cell cycle genes ([@B70]). In humans, it is a crucial transcription factor for normal lung development ([@B1]). Moreover, methylation of *GATA4* gene has been found to regulate oxidative stress and/or airway inflammation, which is related to the health status of patients with COPD ([@B86]). Therefore, methylation of *GATA4* gene in sputum may independently predict the health status of patients with COPD ([@B52]). P16 mediated cell cycle arrest and senescence ([@B79]), The absence of p16 activated the accumulation of Akt and cyclin D, upregulated IGF1 pathway, promoted the proliferation and regeneration of aecii, and finally effectively prevented the cigarette induced emphysema ([@B18]). Of course, there are also some researchers who are opposed to the protective effect of p16, but the sample size of relevant studies is very small (only 3 cases), and the reliability of the results needs further study ([@B75]).

The methylation pattern of tumor suppressor gene (TSG) promoter was studied in sputum samples of patients with COPD; they included cyclin dependent kinase inhibitor 2A ([@B4]), *MGMT* ([@B3]), and *CDH1* ([@B21]). The extent of methylation in *CDKN2A* and *MGMT* was significantly higher. Induction of abnormal methylation in TSG in sputum samples could be a useful tool for early diagnosis of COPD ([@B30]).

Biomarker in Tracheal Epithelium and Lung Tissue {#S4}
================================================

COPD is a heterogeneous inflammatory disease of the airways, alveolus, and microvasculature ([@B66]). Since DNAm in lung tissue ([@B14]; [@B54]) and small airway tissue ([@B84]) is closely related to COPD, tissue-specific DNAm may be considered to occur in COPD. Unlike the hypomethylation pattern of DNAm in blood ([@B64]), most differentially methylated genes in COPD-associated small airway epithelia (SAE) are hypermethylated. Although collection of samples of airway and lung tissues is difficult, a large volume of literature exists regarding DNAm markers in tracheal epithelium and lung tissues ([Table 1](#T1){ref-type="table"}).

###### 

Potential DNA methylation markers in tracheal epithelium and lung tissue of COPD.

  References   Gene                                                   Tissue
  ------------ ------------------------------------------------------ ----------------------------------------------------
  [@B17]       OAT, GRIK2                                             Parenchymal fibroblasts
  [@B55]       KCNK3, EEFSEC, PIK3CD, DCDC2C, TCERG1L, FRMD4B, IL27   Lung tissue
  [@B63]       Klotho                                                 Human bronchial epithelial
  [@B76]       NOS1AP, TNFAIP2, BID, GABRB1, ATXN7, THOC7             Lung tissue
  [@B2]        S1PR5                                                  Alveolar macrophages
  [@B72]       SPDEF, FOXA2                                           Bronchial tissue (primary airway epithelial cells)
  [@B54]       FRMD4A, THSD4, C10orf11                                Lung tissue
  [@B87]       EPAS1                                                  Lung tissue

In view of the common genetic and epigenetic variation of COPD, some researchers follow the results of GWAS as a guide to prioritize the identified loci related to COPD ([@B55]) with epigenetic annotation ([@B42]), and highlight the mechanisms related to complex traits. The genetic control of DNAm has been observed in a variety of complex traits and diseases ([@B58]; [@B32]; [@B5]). [@B54] had analyzed the whole genome DNAm of homogenous lung tissue samples from patients with COPD. The differential methylation sites were integrated with previous genome-wide studies and four of them, namely *CHRM1*, *DTX1*, *GLT1D1*, and *C10orf11*, were focused upon in the study ([@B54]). The *CHRM1* is known to be associated with airway constriction, and a small candidate gene study had shown it to be associated with asthma ([@B49]) and nicotine dependence ([@B45]). In addition, the role of other muscarinic receptor genes had also been previously reported in COPD ([@B15]).

In the lung parenchyma of patients with COPD, researchers had found differentially methylated genes to be closely related to the top typical pathways (such as β-γ signal or cancer mechanism), diseases and disorders (tissue damage and abnormality, cancer and respiratory system diseases), and molecular and cellular functions ([@B76]). Genomic DNAm analysis had confirmed the changes in DNAm status of suggestive genes such as *NOS1AP*, *TNFAIP2*, *BID*, *GABRB1*, *ATXN7*, and *THOC7* in COPD-lung tissue, and further verified the changes by pyrosequencing. DNAm was suggested to possibly play a key role in the regulation of gene expression related to molecular pathways and cellular processes in COPD ([@B86]). Small airways are the main sites of airflow obstruction in patients with COPD; therefore, detection of markers in small-airway epithelium of patients with COPD could have important biological and clinical significance. Three pathways in SAE were found to have potential significance in the pathogenesis of COPD, namely phosphatase and tensin homolog (PTEN) signal, NF-E2-related factor 2 (Nrf2) mediated oxidative stress, and interleukin-17F(IL-17F) inflammatory response pathway ([@B84]).

DNAm has a high level of cell-type specificity, there are some studies on DNAm of individual cell types in patients with COPD. [@B17] had studied the genomic DNAm of fibroblasts isolated from lung parenchyma and airway, and found DNAm to be related to differential gene expression only in the parenchymal fibroblasts. In addition, 359 individual differential CpG loci were found in the parenchymal fibroblasts. The methylation sites of OAT and GRIK2 genes significantly increased their expression in COPD cells ([@B17]). [@B2] had found phagocytosis of apoptotic cells by alveolar macrophages in patients with COPD to be controlled by epigenetic regulation, and decrease of methylation to possibly be the cause of increased S1PR5 gene expression in alveolar macrophages and of the defect in COPD-related efferent cells. Notch-mediated hypermethylation of Klotho in alveolar macrophages and airway epithelial cells inhibited the expression of Klotho and promoted inflammatory response and apoptosis in COPD ([@B63]). Demethylation of NF-κ B-mediated pathway gene is related to the deterioration of COPD. However, TET1/2 plays an important role in the regulation of DNAm and production of cytokine/chemokine by *NF-*κ *B*, *STAT3*, *IKK*, and *NIk* genes in A549 cells ([@B40]).

Goblet cell metaplasia is a common feature of COPD, which is related to mucus hypersecretion. SAM-pointed domain, a transcription factors containing ETS like factor (SPDEF) and forkhead box protein A2 (FOXA2), regulates the differentiation of goblet cells. Airway mucin 5AC, secreted by SPDEF, is aggravated the differentiation of goblet cells and mucin production ([@B60]; [@B12]; [@B67]), while FOXA2 effectively inhibited the differentiation of pulmonary goblet cells ([@B80]). [@B72] had found hypermethylation of CPG-8 in the promoter of *SPDEF* and hypomethylation of CpG-14 and CpG-15 in *FOXA2*, was identified the abnormal methylation of *SPDEF* and *FOXA2* during the differentiation of goblet cells is the basic factor of mucus hypersecretion in COPD, thus providing a new approach to understand mucus hypersecretion from the perspective of epigenetics.

Some researchers had identified key regulatory factors in lung samples of patients with COPD by integrating functional genome, epigenetic data, and higher-order phenotype data ([@B87]). Endothelial PAS domain protein 1 (*EPAS1*) was found to be the only key regulatory factor with a significant overlap of multiple gene sets related to COPD, and the protein level of *EPAS1* was low in the lung tissue of patients with COPD ([@B87]). *EPAS1* is a hypoxia responsive transcription factor, also known as hypoxia inducible factor 2 α (HIF2A) ([@B22]; [@B81]). Its expression in lung and endothelial cells was higher than that of hypoxia inducible factor 1 α (HIF1A). The decrease of *EPAS1* expression observed in COPD actually lead to inadaptability of hypoxia response ([@B41]). Therefore, it would be highly significant to understand the role and mechanism of *EPAS1* in the treatment of diseases.

The above study found significant levels of abnormal DNAm to be different across lung tissues and cell types. It depends on the number of samples ([@B76]), the integration method of gene expression ([@B87]), and the integration scheme with GWAS results ([@B54]).

Discussion {#S5}
==========

DNAm is obviously a potential biomarker for disease prevention, diagnosis, and prognosis. Owing to its reversibility, it has been widely considered as a biomarker and drug design target in COPD. While it has huge prospects in research, there are some limitations in the studies as well. First, the studies were limited by the type of sample: either they were conducted in blood, related to blood biomarkers of the disease (although the transformation of lung pathology was limited), or they are carried out in the lung tissue, where the cell type-specific methylation spectrum could hide the disease-related changes. [@B74] confirmed that DNA methylation from peripheral blood can serve as a surrogate marker for DNA methylation in lung tissue, which shows that it is feasible to search for cross tissue DNA methylation markers (especially in blood and lung tissue) in COPD patients. Moreover, mixed cell population in the whole tissue might complicate the study of the mechanism of cell type-specificity in subsequent diseases. Second, cross-sectional studies hindered the causal relationship between methylation changes and COPD status or lung function level. We are not sure whether these are prior to COPD or the result of COPD. Finally, the studies focused on the European population, with few methylation and transcriptome data from other populations, such as the Asians.

Nevertheless, DNAm as a potential biomarker of COPD, has a broad research prospect. First of all, COPD, as a non-neoplastic lesion, often occurs simultaneously with lung cancer ([@B82]; [@B50]). Hypermethylation of *IL-12RBETA2* and *WIF-1* has been found frequently in the transition from COPD to lung cancer ([@B77]). Therefore, COPD and lung cancer are suggested to be an epigenetic continuum characterized by the accumulation of methylation markers over time. In addition, large-scale methylation studies may help to reveal the details of epigenetic development of COPD into lung cancer, which would be of great significance to public health. Second, the discovery of CRISPR-Cas9 has promoted the development of epigenetic editing ([@B85]). Its advantages in targeting, safety, and preventing non-targeting effect make epigenetic editing, based on epigenetic markers, feasible. In addition, unlike genome editing, epigenetic editing does not lead to permanent changes in the genome. The core of its function is to correct abnormal epigenetic markers to affect the expression or function of specific genes. This could provide a very effective method for the treatment of COPD in future. It is also urgent to obtain dynamic and persistent information of epigenetic markers for different cell types.
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